Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abvc Biopharma (ABVC) Net Margin (2016 - 2025)

Historic Net Margin for Abvc Biopharma (ABVC) over the last 13 years, with Q3 2025 value amounting to 161.76%.

  • Abvc Biopharma's Net Margin fell 1138300.0% to 161.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 1779.54%, marking a year-over-year increase of 32661900.0%. This contributed to the annual value of 1032.02% for FY2024, which is 81544000.0% up from last year.
  • Per Abvc Biopharma's latest filing, its Net Margin stood at 161.76% for Q3 2025, which was down 1138300.0% from 1802.63% recorded in Q2 2025.
  • In the past 5 years, Abvc Biopharma's Net Margin registered a high of 528546.24% during Q4 2024, and its lowest value of 242959.67% during Q1 2024.
  • Moreover, its 5-year median value for Net Margin was 864.46% (2024), whereas its average is 1422.45%.
  • Within the past 5 years, the most significant YoY rise in Abvc Biopharma's Net Margin was 2000000000bps (2024), while the steepest drop was 2000000000bps (2024).
  • Abvc Biopharma's Net Margin (Quarter) stood at 2015.36% in 2021, then plummeted by -141bps to 825.8% in 2022, then crashed by -19208bps to 159442.68% in 2023, then skyrocketed by 431bps to 528546.24% in 2024, then crashed by -100bps to 161.76% in 2025.
  • Its Net Margin stands at 161.76% for Q3 2025, versus 1802.63% for Q2 2025 and 401.85% for Q1 2025.